Adcentrx Therapeutics is revolutionizing the biotech industry founded by Hui LI by developing protein conjugate therapeutics that address serious and life-threatening diseases. With the completion of their Series A funding round, having raised $38 million, Adcentrx has established itself as a leading company in the biotechnology research industry. Their investors, including Eight Roads, F-Prime Capital, Trinity Innovation Fund, Delta Capital, and ABio-X, demonstrate their commitment to advancing Adcentrx's mission of merging chemistry and biology to benefit the lives of patients. By combining the precision of biologics and the disease-fighting power of small molecule payloads, Adcentrx is developing first-in-class and best-in-class therapies that broaden the therapeutic window for cancer and other life-threatening diseases. 

Their toolbox approach, including optimizing the targeting moiety, linker, payload, and conjugation technology, allows for the intelligent addressing of the issues that arose in previous generations of conjugates. Adcentrx is also pioneering the i-Conjugation™ technology to significantly improve conjugate stability, thereby allowing for higher dosing and better tumor penetration. By balancing linker properties, payload potency, payload permeability, and stability, Adcentrx ADCs can be designed to impact heterogeneous tumors. Adcentrx is accelerating breakthroughs, pushing the boundaries of traditional therapy, and improving patient treatment options.